Sun10202019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Writing Service Review
    Writing Service Review
  • Microsoft Exam
    Microsoft Exam
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update


LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results and is providing a business update for the first quarter ended March 31, 2019.
Corporate Highlights in 2019:First biotechnology company to close initial public offering in 2019 and commence trading on The Nasdaq Capital Market.Received the Part the Cloud Award from the Alzheimer’s Association, including a $1 million grant to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease.“2019 has marked a transformative period for INmune Bio, as the first biotech of the year to close its IPO and list on the Nasdaq,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We are focused on advancing our clinical programs for the foreseeable future.” Our clinical programs continue to advance:INB03, our program targeting resistance to immunotherapy caused by myeloid derived suppressor ells (MDSC), completing a monotherapy Phase I trial in patients with advanced solid tumors, will transition into a combination therapy clinical program this summer in preparation for a Phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC that should begin in 2020.  INB03 targets MDSC - one of the causes of resistance to checkpoint inhibitors.  Treatment with INB03 should eliminate the MDSC in the tumor microenvironment to allow CPI to be therapeutically effective.INKmune, our NK cell therapy focused on eliminating residual disease after cancer therapy will start enrolling patients in a Phase I/II trial in women with relapsed refractory ovarian cancer later this year.  In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of their NK cells to eliminate minimal residual disease (MRD).  INKmune, by priming the patient’s NK cells to attack their tumor, should eliminate MRD to prevent relapse.


Posted: 2019-05-15 13:03:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Cable Onda Financial Update

Thu, 17 Oct 2019 23:45:00 GMT

Luxembourg, 18 October 2019 - Millicom announced today that its subsidiary ... management fees and repayment of shareholder loans; and - Other factors or trends affecting our financial condition or ...

Steel Connect Reports Financial Results for Fiscal Year 2019 and the Fourth Quarter

Tue, 15 Oct 2019 15:30:00 GMT

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. SEE ALSO: Warren Buffett reportedly wants the Fed's permission to boost Berkshire's stake in Bank ...

Tesla Announces Date for Third Quarter 2019 Financial Results and Webcast

Wed, 09 Oct 2019 14:08:00 GMT

At that time, Tesla will issue a brief advisory containing a link to the Q3 2019 Update Letter ... of Tesla Q3 2019 Financial Results and Q&A Webcast When: Wednesday, October 23, 2019 Time: 3:30pm ...

Nabis Holdings Provides Shareholder Update and Reports Third Quarter 2019 Financial Results

Wed, 02 Oct 2019 09:15:00 GMT

reported its financial results for the third quarter ended July 31, 2019. All financial information is provided in Canadian dollars unless otherwise indicated. "We continue to make progress on our ...

Nabis Holdings Provides Shareholder Update and Reports Third Quarter 2019 Financial Results

Wed, 02 Oct 2019 04:39:00 GMT

reported its financial results for the third quarter ended July 31, 2019. All financial information is provided in Canadian dollars unless otherwise indicated. “We continue to make progress on our ...

Related News Story Videos From Youtube

No Borders, Inc. Shareholder Update Video - Septemberr 12, 2019


Related Videos On: No Borders, Inc. Shareholder Update Video - Septemberr 12, 2019


No Borders, Inc. Shareholder Update Video - August 15th, 2019


Related Videos On: No Borders, Inc. Shareholder Update Video - August 15th, 2019


2018/2019 Full Year Financial Results #SafaricomFYResults


Related Videos On: 2018/2019 Full Year Financial Results #SafaricomFYResults


Tesla Q1 2019 Earnings Call (no ads)


Related Videos On: Tesla Q1 2019 Earnings Call (no ads)


Financial Results Q3 2018


Related Videos On: Financial Results Q3 2018







Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.